Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 48,300 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the transaction, the chief operating officer directly owned 215,011 shares in the company, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Anish Patel also recently made the following trade(s):

• On Monday, December 8th, Anish Patel sold 6,663 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.02, for a total transaction of $140,056.26.
• On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.40, for a total transaction of $116,005.80.

Enliven Therapeutics Price Performance

ELVN stock traded up $0.72 during trading on Tuesday, reaching $25.75. The company had a trading volume of 1,034,211 shares, compared to its average volume of 2,488,710. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $29.98. The company has a market cap of $1.53 billion, a P/E ratio of -13.99 and a beta of 0.41. The business has a 50 day moving average of $19.17 and a 200 day moving average of $19.97.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Key Enliven Therapeutics News

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: Technical/momentum signal — media coverage flagged rising relative price strength for ELVN, which can attract momentum traders and short‑term inflows. Read More.
• Positive Sentiment: Recent quarterly print beat expectations (reported ($0.32) vs. consensus ($0.43) in Nov.), which remains a constructive fundamental datapoint cited in coverage and analyst models. Read More.
• Neutral Sentiment: Upcoming clinical-data catalyst — analysts and commentators note Enliven is entering 2026 with planned data readouts; that creates event-driven upside but also keeps some investors cautious until results arrive. Read More.
• Neutral Sentiment: Short-interest reporting showed an anomalous zero reading as of Jan 12, which provides no clear bearish or bullish signal and is likely noise rather than an explanatory factor for today’s move.
• Negative Sentiment: Significant insider selling — CEO/insider Joseph P. Lyssikatos sold large blocks across Jan 8–9 (multiple Form 4s totaling ~132k shares across filings) and Director Richard Heyman also sold on Jan 8–9; these sales reduced insider stakes and represent material supply that can weigh on sentiment. SEC filings: Read More. and Read More.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ELVN shares. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.00.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in shares of Enliven Therapeutics by 30.2% in the third quarter. JPMorgan Chase & Co. now owns 24,818 shares of the company’s stock worth $508,000 after purchasing an additional 5,754 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Enliven Therapeutics during the third quarter valued at $334,000. Vestal Point Capital LP increased its holdings in Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock worth $23,745,000 after buying an additional 910,000 shares in the last quarter. Polar Capital Holdings Plc raised its position in Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock worth $63,355,000 after buying an additional 44,713 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Enliven Therapeutics by 19.8% during the 3rd quarter. Millennium Management LLC now owns 381,405 shares of the company’s stock valued at $7,807,000 after acquiring an additional 62,956 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.